Skip to main content

and
  1. No Access

    Article

    Symptom- und Belastungserfassung mit MIDOS oder IPOS – Kennzahl Symptom- und Bedarfserfassung, KeSBa-Projekt

    Servet Para, A. Letsch, B. Alt-Ep**, D. Wecht, M. Naegele, M. Meßmann, U. Krug in Forum (2022)

  2. No Access

    Article

    Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia

    We randomized 3375 adults with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome to test whether increasingly intensive chemotherapies assigned at study-entry and analyzed on a...

    U Krug, W E Berdel, R P Gale, C Haferlach, S Schnittger, C Müller-Tidow in Leukemia (2016)

  3. No Access

    Article

    Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia

    DNA methylation changes are a constant feature of acute myeloid leukemia. Hypomethylating drugs such as azacitidine are active in acute myeloid leukemia (AML) as monotherapy. Azacitidine monotherapy is not cur...

    C Müller-Tidow, P Tschanter, C Röllig, C Thiede, A Koschmieder, M Stelljes in Leukemia (2016)

  4. No Access

    Article

    Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT

    Non-relapse mortality after Allo-SCT has significantly decreased over the last years. Nevertheless, relapse remains a major cause for post SCT mortality in patients with AML and high-risk myelodysplastic syndr...

    T Sauer, G Silling, C Groth, F Rosenow, U Krug, D Görlich in Bone Marrow Transplantation (2015)

  5. No Access

    Article

    CD34+ lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT

    After allo-SCT, analysis of CD34+ lineage-specific donor cell chimerism (DCC) is a sensitive method for monitoring minimal residual disease in patients with AML or myelodysplastic syndrome (MDS) with CD34 express...

    F Rosenow, A Berkemeier, U Krug, C Müller-Tidow, J Gerss in Bone Marrow Transplantation (2013)

  6. No Access

    Article

    High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases

    Germ cell cancer (GCC) is curable in metastatic stages. The International Germ Cell Cancer Collaborative Group (IGCCCG) reports a poor prognosis subgroup with a 5-year survival of 48%. High-dose chemotherapy w...

    M Mohr, I Hartig, T Kessler, C Hamisch, S Kliesch, U Krug in Bone Marrow Transplantation (2012)

  7. No Access

    Article

    The emergence of a C/EBPα mutation in the clonal evolution of MDS towards secondary AML

    Recently, mutations in the transcription factor CCAAT/ enhancer binding protein alpha (C/EBPα) have been described in acute myeloid leukemia (AML). We performed a mutational analysis of the C/EBPα gene in the ...

    A Kaeferstein, U Krug, J Tiesmeier, M Aivado, M Faulhaber, M Stadler, J Krauter in Leukemia (2003)

  8. No Access

    Article

    Unreifzellige myeloische Leukämie

    Die klinischen Befunde von 14 Patienten mit unreifzelliger myeloischer Leukämie werden in knapper Form mitgeteilt. An den leukämischen Zellen (Myeloblasten, Promyelozyten) wurden folgende Untersuchungen durchg...

    D. Huhn, F. Schmalzl, U. Krug in Blut (1971)

  9. No Access

    Article

    Referate

    Walther Stich, D. Schmidt, Susanna R. Hollán, H. G. Arlt, U. Krug, M. Eulitz in Blut (1971)

  10. No Access

    Article

    Buchbesprechungen

    W. Spielmann, W. Stich, U. Krug, F. Scheiffarth, W. Mempel, D. Huhn in Blut (1970)

  11. No Access

    Article

    Referate

    U. Krug, E. Krug in Blut (1970)

  12. No Access

    Article

    Referate

    U. Krug, P. Dörmer, H. H. v. Albert, D. Huhn in Blut (1970)

  13. No Access

    Article

    Buchbesprechungen

    P. Dörmer, R. Marx, U. Krug in Blut (1970)